ArticleViruses2018
Favipiravir and Ribavirin Inhibit Replication of Asian and African Strains of Zika Virus in Different Cell Models.
Article in Viruses, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 89 citations in OpenAlex.
- Drug repositioning as a promising approach for the eradication of emerging and re-emerging viral agents.Molecular diversity · 2025Review
- Advances and Challenges in Vaccination and Therapeutic Strategies Against Japanese Encephalitis Virus.Pathogens (Basel, Switzerland) · 2025Review
- Ginsenoside Rb2 demonstrates potent antiviral activity against Zika virus infection.Journal of ginseng research · 2025Article
- Inhibiting kinesin family member 20A disrupts Zika virus entry by blocking internalization.Journal of microbiology (Seoul, Korea) · 2025Article
- Exploring Iguape Virus-A Lesser-Known Orthoflavivirus.Viruses · 2024Review
- An equine iPSC-based phenotypic screening platform identifies pro- and anti-viral molecules against West Nile virus.Veterinary research · 2024Article
- In vitro bio-characterization of solid lipid nanoparticles of favipiravir in A549 human lung epithelial cancer cells.Journal of Taibah University Medical Sciences · 2023Article
- Development of an Antiviral Ion-Activated In Situ Gel Containing 18β-Glycyrrhetinic Acid: A Promising Alternative against Respiratory Syncytial Virus.Pharmaceutics · 2023Article
- Zika virus modulates mitochondrial dynamics, mitophagy, and mitochondria-derived vesicles to facilitate viral replication in trophoblast cells.Frontiers in immunology · 2023Article
- Evaluation of the Effects of Favipiravir Combined with Vitamin C on Alveolar Bone in Rats.Journal of evolutionary biochemistry and physiology · 2022Article
- Host Molecules Regulating Neural Invasion of Zika Virus and Drug Repurposing Strategy.Frontiers in microbiology · 2022Review
- Searching Anti-Zika Virus Activity in 1Molecules (Basel, Switzerland) · 2021Article
- Nonstructural Protein NS1 of Influenza Virus Disrupts Mitochondrial Dynamics and Enhances Mitophagy via ULK1 and BNIP3.Viruses · 2021Article
- Novel Nonnucleoside Inhibitors of Zika Virus Polymerase Identified through the Screening of an Open Library of Antikinetoplastid Compounds.Antimicrobial agents and chemotherapy · 2021Article
- Favipiravir (T-705) Protects IFNARMicroorganisms · 2021Article
- Glossary of phytoconstituents: Can these be repurposed against SARS CoV-2? A quick in silico screening of various phytoconstituents from plant Glycyrrhiza glabra with SARS CoV-2 main protease.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2021Article
- Article
- Zika virus pathogenesis and current therapeutic advances.Pathogens and global health · 2021Review
- CVB3-Mediated Mitophagy Plays an Important Role in Viral ReplicationFrontiers in cellular and infection microbiology · 2021Article
- Broadly Active Antiviral Compounds Disturb Zika Virus Progeny Release Rescuing Virus-Induced Toxicity in Brain Organoids.Viruses · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Zika virus (ZIKV) has recently emerged as a new public health threat. ZIKV infections have caused a wide spectrum of neurological diseases, such as Guillain-Barré syndrome, myelitis, meningoencephalitis, and congenital microcephaly. No effective therapies currently exist for treating patients infected with ZIKV. Herein, we evaluated the anti-viral activity of favipiravir (T-705) and ribavirin against Asian and African strains of ZIKV using different cell models, including human neuronal progenitor cells (hNPCs), human dermal fibroblasts (HDFs), human lung adenocarcinoma cells (A549) and Vero cells. Cells were treated with favipiravir or ribavirin and effects on ZIKV replication were determined using quantitative real-time PCR and plaque assay. Our results demonstrate that favipiravir or ribavirin treatment significantly inhibited ZIKV replication in a dose-dependent manner. Moreover, favipiravir treatment of ZIKV-infected hNPCs led to reduced cell death, enhanced AKT pathway phosphorylation, and increased expression of anti-apoptotic factor B cell lymphoma 2. In conclusion, our results demonstrate conclusively that favipiravir inhibits ZIKV replication and prevents cell death, and can be a promising intervention for ZIKV-associated disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.